Synthesis and antitumor evaluation of novel cyclic arylsulfonylureas: ADME-T and pharmacophore prediction

European Journal of Medicinal Chemistry

Volumn 45, Issue 6, 2010, Pages 2516-2530

  El Deeb, Ibrahim M ^a   Bayoumi, Said M ^a   El Sherbeny, Magda A ^a   Abdel Aziz, Alaa A M ^a,b  

^a MANSOURA UNIVERSITY   (Egypt)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cancer; Diarylsulfonylurea; Imidazolidine; Molecular modeling; Pharmacophore; Pyrimidine; Quinazoline

Indexed keywords

1 (4 CHLOROPHENYL) 3 (4 CHLOROPHENYLSULFONYL)PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 1 (4 CHLOROPHENYL) 3 (4 METHYLPHENYLSULFONYL)PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 1 (4 CHLOROPHENYL) 3 PHENYLSULFONYLPYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 1 (4 METHYLPHENYL) 3 (4 CHLOROPHENYLSULFONYL)PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 1 (4 METHYLPHENYL) 3 (4 METHYLPHENYLSULFONYL)PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 1 (4 METHYLPHENYL) 3 PHENYLSULFONYLPYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 1 PHENYL 3 (4 CHLOROPHENYLSULFONYL)PYRIMIDINEH 2,4,6 (1H,3H,5H)TRIONE; 1 PHENYL 3 (4 METHYLPHENYLSULFONYL)PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 1 PHENYL 3 PHENYLSULFONYLPYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 (3 NITROBENZYLIDENE) 3 (4 CHLOROPHENYLSULFONYL)IMIDAZOLIDINE 2,4 DIONE; 5 (3 NITROBENZYLIDENE) 3 (4 METHYLPHENYLSULFONYL)IMIDAZOLIDINE 2,4 DIONE; 5 (3 NITROBENZYLIDENE) 3 PHENYLSULFONYLIMIDAZOLIDINE 2,4 DIONE; 5 (4 BROMOBENZYLIDENE) 3 (4 CHLOROPHENYLSULFONYL)IMIDAZOLIDINE 2,4 DIONE; 5 (4 BROMOBENZYLIDENE) 3 (4 METHYLPHENYLSULFONYL)IMIDAZOLIDINE 2,4 DIONE; 5 (4 BROMOBENZYLIDENE) 3 PHENYLSULFONYLIMIDAZOLIDINE 2,4 DIONE; 5 (4 CHLOROBENZYLIDENE) 3 (4 CHLOROPHENYLSULFONYL)IMIDAZOLIDINE 2,4 DIONE; 5 (4 CHLOROBENZYLIDENE) 3 (4 METHYLPHENYLSULFONYL)IMIDAZOLIDINE 2,4 DIONE; 5 (4 CHLOROBENZYLIDENE) 3 PHENYLSULFONYLIMIDAZOLIDINE 2,4 DIONE; 5 (4 METHOXYBENZYLIDENE) 3 (4 CHLOROPHENYLSULFONYL)IMIDAZOLIDINE 2,4 DIONE; 5 (4 METHOXYBENZYLIDENE) 3 (4 METHYLPHENYLSULFONYL)IMIDAZOLIDINE 2,4 DIONE; 5 (4 METHOXYBENZYLIDENE) 3 PHENYLSULFONYLIMIDAZOLIDINE 2,4 DIONE; 5 [4 (N,N DIMETHYLAMINO)BENZYLIDENE] 3 (4 CHLOROPHENYLSULFONYL)IMIDAZOLIDINE 2,4 DIONE; 5 [4 (N,N DIMETHYLAMINO)BENZYLIDENE] 3 (4 METHYLPHENYLSULFONYL)IMIDAZOLIDINE 2,4 DIONE; 5 [4 (N,N DIMETHYLAMINO)BENZYLIDENE] 3 PHENYLSULFONYLIMIDAZOLIDINE 2,4 DIONE; 5 BENZYLIDENE 3 (4 CHLOROPHENYLSULFONYL)IMIDAZOLIDINE 2,4 DIONE; 5 BENZYLIDENE 3 (4 METHYLPHENYLSULFONYL)IMIDAZOLIDINE 2,4 DIONE; 5 BENZYLIDENE 3 PHENYLSULFONYLIMIDAZOLIDINE 2,4 DIONE; ANTINEOPLASTIC AGENT; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG INHIBITION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; KIDNEY CANCER; MELANOMA; MOLECULAR MODEL; OVARY CANCER; PHARMACOPHORE; PREDICTION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROPHOBICITY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONYLUREA COMPOUNDS;

EID: 77950865656     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.02.038     Document Type: Article

References (57)

1. Eckhardt S. Recent progress in the development of anticancer agents. Curr. Med. Chem. Anti-Canc. Agents 2 (2002) 419-439
2. Lee C.W., Hong D.H., Han S.B., Jong S.-H., Kim H.C., Fine R.L., Lee S.-H., and Kim H.M. A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in-vitro and in-vivo tumor models. Biochem. Pharmacol. 64 (2002) 473-480
3. Mohamadi F., Spees M.M., and Grindey G.B. Sulfonylureas: a new class of cancer chemotherapeutic agents. J. Med. Chem. 35 (1992) 3012-3016
4. Chern J.W., Leu Y.L., Wang S.S., Jou R., Lee C.F., Tsou P.C., Hsu S.C., Liaw Y.C., and Lin H.M. Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents. J. Med. Chem. 40 (1997) 2276-2286
5. Toth J.E., Grindey G.B., Ehlhardt W.J., Ray J.E., Boder G.B., Bewley J.R., Klingerman K.K., Gates S.B., Rinzel S.M., Schultz R.M., Weir L.C., and Worzalla J.F. Sulfonimidamide analogs of oncolytic sulfonylureas. J. Med. Chem. 40 (1997) 1018-1025
6. Medina J.C., Shan B., Beckmann H., Farrell R.P., Clark D.L., Learned R.M., Roche D., Li A., Baichwal V., Case C., Baeuerle P.A., Rosen T., and Jaen J.C. Novel antineoplastic agents with efficacy against multidrug resistant tumor cells. Bioorg. Med. Chem. Lett. 8 (1998) 2653-2656
7. Medina J.C., Roche D., Shan B., Learned R.M., Frankmoelle W.P., Clark D.L., Rosen T., and Jaen J.C. Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells. Bioorg. Med. Chem. Lett. 9 (1999) 1843-1846
8. Mastrolorenzo A., Scozzafava A., and Supuran C.T. 4-Toluenesulfonylureido derivatives of amines, amino acids and dipeptides: a novel class of potential antitumor agents. Eur. J. Pharm. Sci. 11 (2000) 325-332
9. Howbert J.J., Grossman C.S., Crowell T.A., Rieder B.J., Harper R.W., and Grindey G.B. Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships. J. Med. Chem. 33 (1990) 2393-2407
10. Supuran C.T., Briganti F., Tilli S., Chegwidden W.R., and Scozzafava A. Carbonic anhydrase inhibitors: sulfonamides as antitumor agents?. Bioorg. Med. Chem. 9 (2001) 703-714
11. Scozzafava A., and Supuran C.T. Carbonic anhydrase inhibitors. Arylsulfonylureido- and arylureido-substituted aromatic and heterocyclic sulfonamides: towards selective inhibitors of carbonic anhydrase isozyme I. J. Enzym. Inhib. 14 (1999) 343-363
12. Scozzafava A., and Supuran C.T. Carbonic anhydrase activators. Part 24. High affinity isozymes I, II and IV activators, derivatives of 4-(4-chlorophenylsulfonylureido-aminoacyl)ethyl-1H-imidazole. Eur. J. Pharm. Sci. 10 (2000) 29-41
13. Casini A., Scozzafava A., Mastrolorenzo A., and Supuran C.T. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr. Cancer Drug Targets 2 (2002) 55-75
14. Guan X., Hoffman B.N., McFarland D.C., Gilkerson K.K., Dwivedi C., Erickson A.K., Bebensee S., and Pellegrini J. Glutathione and mercapturic acid conjugates of sulofenur and their activity against a human colon cancer cell line. Drug. Metab. Dispos. 30 (2002) 331-335
15. Forouzesh B., Takimoto C.H., Goetz A., Diab S., Hammond L.A., Smetzer L., Schwartz G., Gazak R., Callaghan J.T., Von Hoff D.D., and Rowinsky E.K. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies. Clin. Cancer Res. 9 (2003) 5540-5549
16. Jung S.H., Song J.S., Lee H.S., Choi S.U., and Lee C.O. Synthesis and evaluation of cytotoxic activity of novel arylsulfonylimidazolidinones. Bioorg. Med. Chem. Lett. 6 (1996) 2553-2558
17. Jung S.H., Song J.S., Lee H.S., Choi S.U., and Lee C.O. Synthesis and evaluation of cytotoxicity of novel arylsulfonylimidazolidinones containing sulfonylurea pharmacophore. Arch. Pharm. Res. 19 (1996) 570-580
18. Jung S.H., and Kwak S.J. Planar structural requirement at 4-position of 1-arylsulfonyl-4-phenyl-4,5-dihydro-2-imidazolones for their cytotoxicity. Arch. Pharm. Res. 20 (1997) 283-287
19. Jung S.H., Lee H.S., Song J.S., Kim W.M., Han S.B., Lee C.W., Lee M.S., Choi D.R., Lee J.A., Chung Y.H., Yoon S.J., Moon E.Y., Hwang H.S., Seong S.K., and Lee D.K. Synthesis and antitumor activity of 4-phenyl-1-arylsulfonyl imidazolidinones. Bioorg. Med. Chem. Lett. 8 (1998) 1547-1550
20. Moon E.Y., Seong S.K., Jung S.H., Lee M., Lee D.K., Rhee D.K., Pyo S., and Yoon S.J. Antitumor activity of 4-phenyl-1-arylsulfonylimidazolidinone, DW2143. Cancer Lett. 140 (1999) 177-187
21. Moon E.Y., Hwang H.S., Choi C.H., Jung S.H., and Yoon S.J. Effect of DW2282 on the induction of methemoglobinemia, hypoglycemia or WBC count and hematological changes. Arch. Phar. Res. 22 (1999) 565-570
22. Hwang H.S., Moon E.Y., Seong S.K., Choi C.H., Chung C.H., Jung S.H., and Yoon S.J. Characterization of the anticancer activity of DW2282, a new anticancer agent. Anticancer Res. 19 (1999) 5087-5093
23. Jung S.H., Kwak S.J., Kim N.D., Lee S.U., and Lee C.O. Stereochemical requirement at 4-position of 4-phenyl-1-arylsulfonylimidazolidinones for their cytotoxicities. Arch. Phar. Res. 23 (2000) 35-41
24. Lee S.H., Park K.L., Choi S.U., Lee C.O., and Jung S.H. Effect of substituents on benzenesulfonyl motif of 4-phenyl-1-arylsulfonylimidazolidinones for their cytotoxicity. Arch. Pharm. Res. 23 (2000) 579-584
25. Kim I.W., and Jung S.H. Recognition of the importance of imidazolidinone motif for cytotoxicity of 4-phenyl-1-arylsulfonylimidazolidinones using thiadiazolidine-1,1-dioxide analogs. Arch. Pharm. Res. 25 (2002) 421-427
26. Kim I., Lee C., Kim H., and Jung S. Importance of sulfonylimidazolidinone motif of 4-phenyl-1-arylsulfonylimidazolidinones for their cytotoxicity: synthesis of 2-benzoyl-4-phenyl[1,2,5]thiazolidine-1,1-dioxides and their cytotoxcity. Arch. Pharm. Res. 26 (2003) 9-14
27. Zuliani V., Carmi C., Rivara M., Fantini M., Lodola A., Vacondio F., Bordi F., Plazzi P.V., Cavazzoni A., Galetti M., Alfieri R.R., Petronini P.G., and Mor M. 5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur. J. Med. Chem. 44 (2009) 3471-3479
28. Kaminskyy D., Zimenkovsky B., and Lesyk R. Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives. Eur. J. Med. Chem. 44 (2009) 3627-3636
29. Mudit M., Khanfar M., Muralidharan A., Thomas S., Shah G.V., van Soest R.W.M., and El Sayed K.A. Discovery, design, and synthesis of anti-metastatic lead phenylmethylene hydantoins inspired by marine natural products. Bioorg. Med. Chem. 17 (2009) 1731-1738
30. Carmi C., Cavazzoni A., Zuliani V., Lodola A., Bordi F., Plazzi P.V., Alfieri R.R., Petronini P.G., and Mor M. 5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity. Bioorg. Med. Chem. Lett. 16 (2006) 4021-4025
31. Rajic Z., Zorc B., Raic-Malic S., Ester K., Kralj M., Pavelic K., Balzarini J., De Clercq E., and Mintas M. Hydantoin derivatives of l- and d-amino acids: synthesis and evaluation of their antiviral and antitumoral activity. Molecules 11 (2006) 837-848
32. Singh P., Kaur M., and Verma P. Design, synthesis and anticancer activities of hybrids of indole and barbituric acids - identification of highly promising leads. Bioorg. Med. Chem. Lett. 19 (2009) 3054-3058
33. Guerin D.J., Mazeas D., Musale M.S., Naguib N.F.M., Al Safarjalani O.N., el Kouni M.H., and Panzica R.P. Uridine phosphorylase inhibitors: chemical modification of benzyloxybenzyl-barbituric acid and its effects on urdpase inhibition. Bioorg. Med. Chem. Lett. 9 (1999) 1477-1480 (and references cited therein)
34. Shrestha A.R., Shindo T., Ashida N., and Nagamatsu T. Synthesis, biological active molecular design, and molecular docking study of novel deazaflavin-cholestane hybrid compounds. Bioorg. Med. Chem. 16 (2008) 8685-8696
35. Choo H.-Y.P., Kim M., Lee S.K., Kim S.W., and Chung S.W. Solid-phase combinatorial synthesis and cytotoxicity of 3-aryl-2,4-quinazolindiones. Bioorg. Med. Chem. 10 (2002) 517-523
36. Billek G. Über die kondensation aromatischer aldehyde mit hydantoin. Monatsh. Chem. 92 (1961) 352-360
37. Thenmozhiyal J.C., Wong P.T., and Chui W.K. Anticonvulsant activity of phenylmethylenehydantoins: a structure-activity relationship study. J. Med. Chem. 47 (2004) 1527-1535
38. Rabjon N. Organic Syntheses, Coll vol. IV (1963), John Wiley and Sons Inc., Canada 49
39. Vogel A.I. Vogel's Textbook of Practical Organic Chemistry. fifth ed (1989), Longman, London p. 963
40. Brückmann G., and Isaacs S.D. Preparation and properties of new derivatives of alloxan. J. Am. Chem. Soc. 71 (1949) 390-392
41. Kurihara M., and Yoda N. Molecular rearrangement in polyphosphoric acid I. Formation of 1, 2-dihydro-2-phenylimino-4H-3,1-benzoxazin-4-one and rearrangement to 3-phenyl-2,4(1H,3H)-quinazolinedione in polyphosphoric acid. Tetrahedron Lett. 30 (1965) 2597-2606
42. Profeta S., and Allinger N.L. Molecular mechanics calculations on aliphatic amines. J. Am. Chem. Soc. 107 (1985) 1907-1918
43. Halgren T.A. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 17 (1996) 490-519
44. MOE 2009.10 of Chemical Computing Group. Inc.
45. Dewar M.J.S., Zoebisch E.G., Healy E.F., and Stewart J.J.P. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 107 (1985) 3902-3909
46. Khodair A.I., and Bertrand P.A. A new approach to the synthesis of substituted 4-imidazolidinones as potential antiviral and antitumor agents. Tetrahedron 54 (1998) 4859-4872
47. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 46 (2001) 3-26
48. Clark D.E., and Pickett S.D. Computational methods for the prediction of 'drug-likeness'. Drug Discov. Today 5 (2000) 49-58
49. Pharma Algorithms (Web Edition) (2009) Toronto, Canada
50. Moda T.L., Torres L.G., Carrara A.E., and Andricopulo A.D. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models. Bioinformatics 24 (2008) 2270-2271
51. Wolber G., Seidel T., Bendix F., and Langer T. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov. Today 13 (2008) 23-29
52. Al-Obaid A.M., Abdel-Hamide S.G., El-Kashef H.A., Abdel-Aziz A.A.-M., El-Azab A.S., Al-Khamees H.A., and El-Subbagh H.I. Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs. Eur. J. Med. Chem. 44 (2009) 2379-2391
53. Choo H.-Y.P., Lim J.-S., Kam Y., Kim S.Y., and Lee J. A comparative study of quantitative structure activity relationship methods based on antitumor diarylsulfonylureas. Eur. J. Med. Chem. 36 (2001) 829-836
54. Choo H.-Y.P., Choi S., Jung S.-H., Koh H.Y., and Pae A.N. The 3D-QSAR study of antitumor arylsulfonylimidazolidinone derivatives by CoMFA and CoMSIA. Bioorg. Med. Chem. 11 (2003) 4585-4589
55. Grever M.R., Sehepartz S.A., and Chabners B.A. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 19 (1992) 622-638
56. Monks A., Schudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., and Boyd M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83 (1991) 757-766
57. Boyd M.R., and Paull K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug. Dev. Res. 34 (1995) 91-109